← Back to Search

Behavioral Intervention

Opioid Taper Before Surgery for Arthritis

N/A
Recruiting
Led By Kevin R Riggs, MD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have a reliable telephone number for contact
Currently taking between 20 and 90 MME of oral opioids, and that dose has been stable for at least 3 months
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from enrollment until approximately 2 weeks after surgery
Awards & highlights

Study Summary

This trial tests a pharmacist-led opioid taper to help those on chronic opioids reduce dose before surgery. A pharmacist provides education and adjusts the taper as needed.

Who is the study for?
This trial is for people planning to have knee or hip replacement surgery in the next 4-8 weeks, who are currently on a stable opioid dose of 20-90 MME for at least three months. Participants must speak English and have a reliable phone number. Those using certain opioids like Buprenorphine or Methadone, long-acting or transdermal opioids cannot join.Check my eligibility
What is being tested?
The study is testing a pharmacist-led program to reduce opioid use before knee or hip surgery. It involves education about pain and opioids, creating an individual tapering plan, and weekly follow-ups by phone to adjust the plan as needed.See study design
What are the potential side effects?
While specific side effects aren't listed for this intervention, reducing opioid doses can lead to withdrawal symptoms such as anxiety, irritability, sleep disturbances, increased pain sensitivity and flu-like symptoms.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a working phone number.
Select...
I have been on a stable dose of 20-90 MME oral opioids for 3 months.
Select...
I am scheduled for knee or hip replacement surgery in the next 4-8 weeks.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from enrollment until approximately 2 weeks after surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and from enrollment until approximately 2 weeks after surgery for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Acceptability
Secondary outcome measures
Perioperative Pain
Study Recruitment Rate
Study Retention Rate
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Pharmacist-led opioid taper interventionExperimental Treatment1 Intervention
The participant will attempt to taper their opioid dose by ~50% during the 4-6 week preoperative period. Participants will meet with a clinical pharmacist, who will provide some basic education on pain and opioids, and will propose an opioid taper schedule. The pharmacist will then follow-up with the participant by phone each week until surgery to assess progress and adjust the taper as necessary.

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,573 Previous Clinical Trials
2,273,234 Total Patients Enrolled
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NIH
483 Previous Clinical Trials
1,086,894 Total Patients Enrolled
Kevin R Riggs, MDPrincipal InvestigatorUniversity of Alabama at Birmingham

Media Library

Opioid Taper Intervention (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05788016 — N/A
Hip Arthritis Research Study Groups: Pharmacist-led opioid taper intervention
Hip Arthritis Clinical Trial 2023: Opioid Taper Intervention Highlights & Side Effects. Trial Name: NCT05788016 — N/A
Opioid Taper Intervention (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05788016 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research endeavor presently admitting participants?

"According to the information provided on clinicaltrials.gov, this particular trial is not currently accepting applications. It was posted initially in April 1st 2023 and last updated on March 15th 2023. Although no longer recruiting participants, there are 803 other studies presently seeking candidates."

Answered by AI
~0 spots leftby Apr 2024